Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis

Innovent Biologics

Yesterday 11:48

Corrects dateline
Nov 3 (Reuters) - Pfizer PFE.N raised its annual profit and revenue forecasts on Tuesday, banking on strong demand for its blood thinner Eliquis.
The U.S. drugmaker expects annual sales of $62 billion to $64.0 billion, up from $60.5 billion to $62.5 billion forecast previously.
It expects to earn adjusted per-share of $2.95 to $3.05 this year, compared with previous forecast of $2.80 to $3.00 per share.
Analysts' on average were expecting annual per-share profit of $2.96 and 2026 revenue of $62.17 billion.

 (Reporting by Christy Santhosh and Mariam Sunny in Bengaluru; Editing by Arun Koyyur)
 ((Christy.Santhosh@thomsonreuters.com;))